About
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Visit company website
5 years, 5 months ago
Morepen Laboratories Limited is currently in a long term uptrend where the price is trading 86.0% above its 200 day moving average.
From a valuation standpoint, the stock is 72.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Morepen Laboratories Limited's total revenue rose by 33.6% to $3B since the same quarter in the previous year.
Its net income has increased by 120.0% to $238M since the same quarter in the previous year.
Finally, its free cash flow grew by 352.0% to $200M since the same quarter in the previous year.
Based on the above factors, Morepen Laboratories Limited gets an overall score of 5/5.